Study identification

EU PAS number

EUPAS1000000665

Study ID

1000000665

Official title and acronym

DARWIN EU® - Drug Utilisation Study on Antibiotics in the ‘Watch’ category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use

DARWIN EU® study

Yes

Study countries

Croatia
Denmark
Finland
France
Germany
Hungary
Netherlands
Spain

Study description

The WHO 2023 ‎AWaRe classification‎ (who.int) of antibiotics for evaluation and monitoring of use classifies 258 antibiotics into 3 categories (Access/Watch/Reserve) according to their impact on antimicrobial resistance.
The Watch list includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents among the Critically Important Antimicrobials for Human Medicine and/or antibiotics that are at relatively high risk of selection of bacterial resistance. These medicines should be prioritized as key targets of stewardship programs and monitoring.
The DARWIN EU®_ P1-C1-003 study focused on the Watch category and this study is now repeated to include more recent data and more data sources.
This study will improve our understanding of the use of antibiotics in the Watch category in routine health care delivery, including indication, treatment duration and trends over time. The results will contribute to the EU efforts to monitor use of antibiotics as part of the global fight against antimicrobial resistance.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Marzyeh Amini

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable